ArticleFrontiers in oncology2025
Case Report: A rare case of thyroid metastasis from breast cancer.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: To analyze the clinicopathological features, diagnosis, and treatment strategies for metastatic breast carcinoma to the thyroid (MBCT) to enhance clinical awareness of this rare condition. Methods: Analysis of clinical data from one MBCT patient and literature review. Results: A 41-year-old female with left breast invasive ductal carcinoma (IDC) received neoadjuvant AC-T chemotherapy, breast-conserving surgery, radiotherapy, and endocrine therapy. At eight years post-diagnosis, thyroid lesions were detected. Total thyroidectomy with lymph node dissection confirmed MBCT pathologically. No progression was observed at 16 months post-thyroidectomy. Conclusions: MBCT is a rare clinical entity characterized by nonspecific clinical and radiological findings. Immunohistochemical (IHC) analysis is essential for a definitive diagnosis. In patients with a breast cancer history, MBCT should always be considered in the differential diagnosis of thyroid abnormalities.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.